On-demand Webinar
The GLP-1 cost crisis: What can you do?
About the webinar
Some of the largest organizations in the US spend upwards of $16,000 per person per year on costs associated with GLP-1s.
How much are you willing to spend on GLP-1s annually?
Regardless of company or plan size, the costs associated with these life-changing anti-obesity medications are astounding and often unmanaged. Leaders walk a fine line between wanting to offer the best care for obesity — one of America’s most prevalent chronic health conditions — and needing to be fiscally responsible.
The good news is you don’t have to pull never-ending dollars from your coffers to give care at the right time to your people. Obesity step therapy is a clinically-proven treatment that provides acuity-based treatment — meaning if you need a GLP-1, you’ll be prescribed one, but if you don’t, a provider will recommend the right treatment.
In this webinar, Vida’s own Sr. Director of Cardiometabolic and Prescribing, Gretchen Zimmermann, joined Chief Medical Officer Dr. Richard Frank to discuss:
- What obesity step therapy is and how it can dramatically reduce GLP-1 costs
- How GLP-1 and other anti-obesity medications can be properly managed without costly lifetime prescriptions
- Why step therapy helps organizations sustain and scale clinical and engagement outcomes
